Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 20/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 3/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6903749 | 1.00 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL407673 | 1.00 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL667262 | 1.00 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL5070367 | 0.94 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL28483063 | 0.94 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL5070366 | 0.94 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL21512474 | 0.94 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL5070365 | 0.94 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL1881237 | 0.93 | ESR1 (0.87) | ESR1ESR2PGR | |
| SCHEMBL1881240 | 0.93 | ESR1 (0.87) | ESR1ESR2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3400210-B1 | \"MULTI-TARGET\" COMPOUNDS WITH INHIBITORY ACTIVITY TOWARDS HISTONE DEACETYLASES AND TUBULIN POLYMERISATION, FOR USE IN THE TREATMENT OF CANCER | UNIV PARIS SACLAY (FR) | 2021-09-29 | — | — | EP | claimed |
| US-11014871-B2 | “Multi-target” compounds with inhibitory activity towards histone deacetylases and tubulin polymerisation, for use in the treatment of cancer | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2021-05-25 | — | — | US | claimed |
| WO-2019057920-A1 | BORONATE ESTER CROSSLINKED NANOGELS BASED ON MODIFIED POLYSACCHARIDES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-03-28 | — | — | WO | claimed |
| EP-2142493-B1 | ISO CA-4 AND ANALOGUES THEREOF AS POTENT CYTOTOXIC AGENTS INHIBITING TUBULINE POLYMERISATION | CENTRE NAT RECH SCIENT (FR) | 2019-03-27 | — | — | EP | claimed |
| US-20190023645-A1 | \"MULTI-TARGET\" COMPOUNDS WITH INHIBITORY ACTIVITY TOWARDS HISTONE DEACETYLASES AND TUBULIN POLYMERISATION, FOR USE IN THE TREATMENT OF CANCER | UNIVERSITE PARIS-SUD (FR) | 2019-01-24 | — | — | US | claimed |
| EP-3400210-A2 | \"MULTI-TARGET\" COMPOUNDS WITH INHIBITORY ACTIVITY TOWARDS HISTONE DEACETYLASES AND TUBULIN POLYMERISATION, FOR USE IN THE TREATMENT OF CANCER | Universite Paris-Sud (FR) | 2018-11-14 | — | — | EP | claimed |
| US-20170266166-A1 | Compositions and Methods to Inhibit Estrogen Receptor Beta for the Treatment of Renal Cell Carcinoma | UNIV ROCHESTER (US) | 2017-09-21 | — | — | US | claimed |
| WO-2015179239-A1 | COMPOSITIONS AND METHODS TO INHIBIT ESTROGEN RECEPTOR BETA FOR THE TREATMENT OF RENAL CELL CARCINOMA | UNIVERSITY OF ROCHESTER (US) | 2015-11-26 | — | — | WO | claimed |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | claimed |
| JP-2001513525-A | — | — | 2001-09-04 | — | — | JP | claimed |
| US-6207716-B1 | FOR PROPHYLAXIS AND THERAPY OF OSTEOPOROSIS, ARTHRITIS, BREAST CANCER, CARDIOVASCULAR DISEASE | GLAXO WELLCOME INC. | 2001-03-27 | — | — | US | claimed |
| US-6124314-A | A PROSTAGLANDIN AGONISTS FOR TREATING VERTEBRATE BONE DISORDERS | PFIZER INC. (US) | 2000-09-26 | — | — | US | claimed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | claimed |
| EP-0946501-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | claimed |
| EP-0911321-A2 | Compounds for the treatment of osteoporosis | PFIZER INC. (US) | 1999-04-28 | — | — | EP | claimed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | claimed |
| WO-1999007668-A1 | NON-STEROIDAL LIGANDS FOR THE ESTROGEN RECEPTOR | GLAXO WELLCOME INC. (US) | 1999-02-18 | — | — | WO | claimed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | claimed |
| US-5681835-A | USEFUL FOR TREATING OSTEOPOROSIS | GLAXO WELLCOME INC. (US) | 1997-10-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | ESR1 303/4885ESR2 616/4885PGR 408/4885 |
| US-20190023645-A1 | \"MULTI-TARGET\" COMPOUNDS WITH INHIBITORY ACTIVITY TOWARDS HISTONE DEACETYLASES AND TUBULIN POLYMERISATION, FOR USE IN THE TREATMENT OF CANCER | HDAC6, HDAC1, HDAC5 | ESR1 4076/4885ESR2 3348/4885PGR 3010/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | ESR1 303/4885ESR2 616/4885PGR 408/4885 |
| US-11014871-B2 | “Multi-target” compounds with inhibitory activity towards histone deacetylases and tubulin polymerisation, for use in the treatment of cancer | HDAC6, HDAC1, HDAC5 | ESR1 4151/4885ESR2 3649/4885PGR 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.